Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03000595
Other study ID # SAN007-03
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date June 2018
Est. completion date January 2019

Study information

Verified date January 2019
Source Santalis Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28 days to patients from 3 months to 65 years of age, with atopic dermatitis.


Description:

Patients will enter the Screening Period once the informed consent/ascent and photographic consent process has been completed. Patients with a total body surface area (BSA) of ≥2% and ≤ 15% atopic dermatitis involvement, in the treatable areas, and who meet all of the inclusion and none of the exclusion criteria will be enrolled.

Once patient eligibility is confirmed and the screening procedures completed, the patient will start the Treatment Period of the study. All enrolled patients will receive either 5% SAN007 cream or placebo cream (randomized in a 2:1 ratio) with the first dose applied at the Day 1 Study Visit. Patients and/or their legally authorized representative will be instructed on how to apply the study medication twice daily for 28 days. Patients will return to the clinic on Study Days 7,14 and 28 for study-related assessments. Patients and/or their LAR will receive a telephone contact from the site, on Study Days 21 and 35.

Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug.

In addition cutaneous tolerability will be evaluated at each visit. Tolerability evaluation will be based on patients reporting discomfort during or immediately following application of SAN007. This will also be recorded as an AE. The study exclusion areas are to be not to be used in this evaluation.

Efficacy will be assessed at each study visit through the completion of the IGA, EASI and BSA calculation.

During the active treatment period, Patients will return to the study site according to the study schedule for interim assessments and recording of concomitant medication and adverse events (AEs).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2019
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group 3 Months to 65 Years
Eligibility Inclusion Criteria:

1. Are at least 3 months of age

2. Have atopic dermatitis, as determined by an EASI score of =5 and =50 (Hanifin, 2001)

3. Total treatment area(s) of atopic dermatitis involvement =2% and =10% body surface area (BSA).

4. Have atopic dermatitis that has been clinically stable for = 1 month prior to the Screening Visit.

5. Are able to obtain written informed consent/ascent in a manner approved by the Institutional Review Board and comply with the requirements of the study.

6. Are willing to refrain from using any lotions, moisturizer, cleansers, cosmetics or creams, other than those issued as part of the study, on the target treatment areas during the treatment period.

7. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events.

8. Are willing to refrain from exposure to artificial ultraviolet radiation for the duration of the study.

9. Are willing to cover target treatment areas to avoid exposure to natural ultraviolet radiation for the duration of the study.

10. If female of childbearing potential, must be willing to practice an acceptable form of birth control for the duration of the study. i.e. barrier method, hormone or intrauterine device.

11. Are willing to avoid participation in any other clinical trial for the duration of this study.

12. Are willing to refrain from treating areas that are not the defined treatment area(s), which will be excluded from all assessments and BSA calculation.

13. Are willing to refrain from treating study restricted areas. Study restricted areas are as follows: head, neck, soles of feet, palms of hands, axillae, or intertriginous areas.

Exclusion Criteria:

1. Have a sibling or immediate family member already participating in this trial.

2. Currently requires and/or, in the past month, has required topical use of a medium or high potency steroid.

3. Atopic dermatitis that, in the opinion of the investigator, is likely to stem from an allergic reaction. (i.e. contact dermatitis)

4. Have <2% of atopic dermatitis involvement eligible for treatment.

5. Have participated in any interventional clinical trial in the previous 30 days to the screening visit.

6. Have a known sensitivity to any of the constituents of the test product including sensitivities to sandalwood oil, fragrances or any member of the Compositae family of vascular plants (e.g., sunflowers, daisies, dahlias, etc.).

7. Have received phototherapy within the last 2 months prior to enrollment.

8. Have received any systemic medication for atopic dermatitis in the past 2 months that would interfere with the evaluation of atopic dermatitis (excluding antihistamines or leukotriene inhibitors).

9. Have a present condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

10. Are pregnant, breast-feeding or plan to become pregnant at any point for the duration of the trial.

11. Are not willing to practice an approved form of birth control while on the study drug for the duration of the trial. i.e. barrier method, hormone or intrauterine device.

12. Have been treated, with prescription medication for atopic dermatitis, with no improvement in condition, within 60 days prior to the Baseline visit.

13. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, or any other confounding skin condition.

14. Have undergone treatments with topical atopic dermatitis drug products, other than retinoids or corticosteroids, within 14 days prior to the Baseline Visit, and for therapy containing corticosteroids or retinoids within 28 days prior to Baseline Visit.

15. Have open sores or open lesions in the treatment area(s).

16. Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past two years.

17. Require greater than 2.0 mg/day inhaled or intranasal corticosteroids.

18. Have an active infection of any kind at Baseline

19. Have an occupation that requires =50% of time be spent outdoors, where prolonged exposure to ultraviolet radiation is unavoidable.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SAN007 Cream
A cream containing 5% East Indian sandalwood oil (EISO).
Placebo
The vehicle cream

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Santalis Pharmaceuticals, Inc. ClinDatrix, Inc., Fremantle Dermatology

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug. 28 days
Primary Incidence of Irritation or Rash at the Site of Application of the Study Medication The percentage of patients reporting discomfort either during or immediately following the application of SAN007. 28 Days
Secondary Percentage of Patients who Achieve an Improvement in Investigator Global Assessment Score The number of patients achieving an Investigator Global Assessment of "clear" or "almost clear" at any time point during therapy 28 Days
Secondary Percentage of Patients who have a = 25% reduction in the Eczema Area and Severity Index (EASI) score Percentage of patients who have a = 25% reduction in the Eczema Area and Severity Index (EASI) score at any point during the trial. 28 days
Secondary Percentage of Patients who have a = 50% reduction in the Eczema Area and Severity Index (EASI) score Percentage of patients who have a = 50% reduction in the Eczema Area and Severity Index (EASI) score at any point during the trial. 28 Days
Secondary Percentage of patients achieving at least a 1-grade improvement in Investigator Global Assessment score Percentage of patients achieving at least a 1-grade improvement in Investigator Global Assessment score 28 Days
Secondary Percentage of patients who have at least a 20% reduction in BSA affected by atopic dermatitis. Percentage of patients who have at least a 20% reduction in BSA affected by atopic dermatitis. 28 Days
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2